Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.
Backes, B.J., Longenecker, K., Hamilton, G.L., Stewart, K., Lai, C., Kopecka, H., von Geldern, T.W., Madar, D.J., Pei, Z., Lubben, T.H., Zinker, B.A., Tian, Z., Ballaron, S.J., Stashko, M.A., Mika, A.K., Beno, D.W., Kempf-Grote, A.J., Black-Schaefer, C., Sham, H.L., Trevillyan, J.M.(2007) Bioorg Med Chem Lett 17: 2005-2012
- PubMed: 17276063 
- DOI: 10.1016/j.bmcl.2007.01.026
- Primary Citation of Related Structures:  
2OAG, 2OAE - PubMed Abstract: 
A novel series of pyrrolidine-constrained phenethylamines were developed as dipeptidyl peptidase IV (DPP4) inhibitors for the treatment of type 2 diabetes. The cyclohexene ring of lead-like screening hit 5 was replaced with a pyrrolidine to enable parall ...